Publications

Detailed Information

A Relationship Between Alzheimer`s Disease and Type 2 Diabetes Mellitus Through the Measurement of Serum Amyloid-beta Autoantibodies

DC Field Value Language
dc.contributor.authorKim, Insub-
dc.contributor.authorLee, Junhee-
dc.contributor.authorHong, Hyun Joo-
dc.contributor.authorJung, Eun Sun-
dc.contributor.authorJeong, In Kyong-
dc.contributor.authorSo, Insuk-
dc.contributor.authorMook-Jung, Inhee-
dc.contributor.authorPark, Kyong Soo-
dc.contributor.authorCho, Young Min-
dc.contributor.authorKu, Yun Hyi-
dc.date.accessioned2012-05-29T08:50:11Z-
dc.date.available2012-05-29T08:50:11Z-
dc.date.issued2010-
dc.identifier.citationJOURNAL OF ALZHEIMERS DISEASE; Vol.19 4; 1371-1376ko_KR
dc.identifier.issn1387-2877-
dc.identifier.urihttps://hdl.handle.net/10371/76575-
dc.description.abstractIncreasing evidence suggests that type 2 diabetes mellitus (T2DM) is strongly correlated with Alzheimer`s disease (AD). To examine the relationship between T2DM and AD, autoantibodies against amyloid-A beta were measured in the serum of T2DM patients and age-matched controls. Levels of A beta autoantibody were measured by ELISA in serum samples of T2DM patients (n = 92) and age-matched control group (n = 106). A beta autoantibody levels were increased in T2DM compared with age-matched controls by 45.4 +/- 8.1% (p < 0.001). Females had higher A beta autoantibody levels than males in both T2DM and control group. A beta autoantibody levels in the T2DM group were positively correlated with the levels of cholesterol (p = 0.011), low density lipoprotein cholesterol (p = 0.020), and triglycerides (p = 0.039). In conclusion, the level of A beta autoantibody is dramatically elevated in patient serum of T2DM, and, as such, might be used as a possible biomarker for T2DM.ko_KR
dc.language.isoenko_KR
dc.publisherIOS PRESSko_KR
dc.subjectA beta Autoantibodyko_KR
dc.subjecttype 2 diabetes mellitusko_KR
dc.subjectcholesterolko_KR
dc.subjectbiomarkerko_KR
dc.subjectAlzheimer`s diseaseko_KR
dc.titleA Relationship Between Alzheimer`s Disease and Type 2 Diabetes Mellitus Through the Measurement of Serum Amyloid-beta Autoantibodiesko_KR
dc.typeArticleko_KR
dc.contributor.AlternativeAuthor김인섭-
dc.contributor.AlternativeAuthor이준희-
dc.contributor.AlternativeAuthor홍현주-
dc.contributor.AlternativeAuthor정은선-
dc.contributor.AlternativeAuthor구윤희-
dc.contributor.AlternativeAuthor정인경-
dc.contributor.AlternativeAuthor조영민-
dc.contributor.AlternativeAuthor소인석-
dc.contributor.AlternativeAuthor박경수-
dc.identifier.doi10.3233/JAD-2010-1332-
dc.citation.journaltitleJOURNAL OF ALZHEIMERS DISEASE-
dc.description.citedreferenceGotz J, 2009, CELL MOL LIFE SCI, V66, P1321, DOI 10.1007/s00018-009-9070-1-
dc.description.citedreferenceSohn JH, 2009, FRONT BIOSCI, V14, P3879, DOI 10.2735/3496-
dc.description.citedreferenceRubinstein R, 2008, CLIN EXP IMMUNOL, V154, P235, DOI 10.1111/j.1365-2249.2008.03742.x-
dc.description.citedreferenceLi L, 2007, BRAIN RES REV, V56, P384, DOI 10.1016/j.brainresrev.2007.09.001-
dc.description.citedreferenceSohn JH, 2007, BIOCHEM BIOPH RES CO, V361, P800, DOI 10.1016/j.bbrc.2007.07.107-
dc.description.citedreferencede la Monte SM, 2006, J ALZHEIMERS DIS, V10, P89-
dc.description.citedreferenceLester-Coll N, 2006, J ALZHEIMERS DIS, V9, P13-
dc.description.citedreferenceDickstein DL, 2006, FASEB J, V20, P426, DOI 10.1096/fj.05-3956com-
dc.description.citedreferenceMoir RD, 2005, J BIOL CHEM, V280, P17458, DOI 10.1074/jbc.M414176200-
dc.description.citedreferenceSteen E, 2005, J ALZHEIMERS DIS, V7, P63-
dc.description.citedreferenceSakowicz M, 2005, INT IMMUNOL, V17, P145, DOI 10.1093/intimm/dxh195-
dc.description.citedreferenceKrentz AJ, 2003, DIABETES OBES METAB, V5, pS19, DOI 10.1046/j.1462-8902.2003.0310.x-
dc.description.citedreferenceSilvius JR, 2003, BBA-BIOMEMBRANES, V1610, P174, DOI 10.1016/S0005-2736(03)00016-6-
dc.description.citedreferencePan WH, 2002, EXP BIOL MED, V227, P609-
dc.description.citedreferenceWeksler ME, 2002, EXP GERONTOL, V37, P943-
dc.description.citedreferenceDeMattos RB, 2002, SCIENCE, V295, P2264-
dc.description.citedreferencePELIA R, 2002, DIABETES, V51, P1256-
dc.description.citedreferenceBard F, 2000, NAT MED, V6, P916-
dc.description.citedreferenceRefolo LM, 2000, NEUROBIOL DIS, V7, P321-
dc.description.citedreferenceOtt A, 1999, NEUROLOGY, V53, P1937-
dc.description.citedreferenceSchenk D, 1999, NATURE, V400, P173-
dc.description.citedreferenceAlberti KGMM, 1998, DIABETIC MED, V15, P539-
dc.description.citedreferenceAlexiewicz JM, 1997, AM J KIDNEY DIS, V30, P98-
dc.description.citedreferenceYankner BA, 1996, NEURON, V16, P921-
dc.description.citedreferenceCLARK A, 1988, DIABETES RES CLIN EX, V9, P151-
dc.description.citedreferenceCOOPER GJS, 1987, P NATL ACAD SCI USA, V84, P8628-
dc.description.tc0-
Appears in Collections:
Files in This Item:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share